ImmuCell Q1 2026 net income $1.9M, product sales up 28.4% to $10.4M

IMMUCELL CORP /DE/

2026-Q1 EPS reported $0.21 revenue$10,357,295

Net income $1.9M ($0.21/share) vs $1.4M ($0.16/share) in Q1 2025.
Product sales $10.4M, up 28.4% YoY; gross margin 45.0% vs 41.6%.
Cash position $6.8M at Mar 31, 2026, up from $3.8M; generated $3.4M free cash flow in Q1.
Settled all disputes with former contract manufacturer for net $2M payment to ImmuCell, to fund capacity expansion.
Manufacturing output increased to >450K units/month from ~380K in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IMMUCELL CORP /DE/ reported the quarter ended March 31, 2026 results: revenue approximately $10.4 million, net income $1.9 million, EPS $0.21 per basic share.

Period: the quarter ended March 31, 2026
Revenue: approximately $10.4 million
Net income: $1.9 million
EPS: $0.21 per basic share
Result: reported results

Exact text from the filing

million compared to the first quarter of 2025,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “These results were driven by 28.4% growth in product sales to $10.4 million and an expansion of gross margins to 45.0% that reflects higher volumes, manufacturing efficiencies, and price realization. ImmuCell generated $3.4 million free cash flow in the

View on SEC.gov

Browse all earnings releases →

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001437749-26-017049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.